NCT00243061View on ClinicalTrials.gov

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Acral Lentiginous Malignant MelanomaCiliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeExtraocular Extension MelanomaIntraocular MelanomaIris MelanomaLentigo Maligna Malignant MelanomaRecurrent MelanomaStage, Intraocular MelanomaStage IV MelanomaSuperficial Spreading Malignant Melanoma
Interventions
DRUG

cediranib maleate

Given orally

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00243061 - AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | Biotech Hunter | Biotech Hunter